Company Profile
| Company Name | ClinChoice K.K. |
| Date of Establishment | October 5, 2015 |
| Representative | Ling Zhen |
| Main business activities | Contracted services for the development of pharmaceuticals, quasi-drugs, cosmetics, and medical devices； The collection of safety information, as well as related labor dispatch； Consultation services, interpretation, and translation services incidental related to the above. |
| Participating organizations | CRO Association of Japan, Inc. CDISC (Gold Member) Japan Clinical Society of Dysarthria Reserch |
| Permits & Certifications | Worker dispatch business license (Hata 13-306970) Adoption of labor-management agreement method “Women Friendly” Certification |
Access
- Location
3-4-1 Higashi-Nihonbashi, Chuo-ku, Tokyo 103-0004, Japan
VORT Higashi-Nihonbashi II, 3rd Floor - By Train
JR Sobu Main Line: 4-minute walk from Exit 1 of Bakurocho Station Shinjuku Line: 2-minute walk from Exit A2 of Bakuroyokoyama Station Asakusa Line: 2-minute walk from Exit A3 of Higashi-Nihonbashi Station - Business Hours
Weekdays: 9:00 AM – 6:00 PM
Closed on Saturdays, Sundays, and public holidays - Tel +81-3-6228-7360
- Fax +81-3-6701-2398
Company History
1995
K&L was founded in Philadelphia, USA.
2007
FMD was founded in Tianjin.
Series A financing led by Draper Fisher Jurvetson.
2012
iMed was founded in the United States and India.
2014
International Development: Merger with K&L;
Series B financing: led by Lilly Asia Ventures.
2016
Global Development: Merger with iMed
Series C financing: led by Lilly Asia Ventures and Draper Fisher Jurvetson.
2019
Series D Financing: Led by Goldman Sachs and Lilly Asia Ventures
New management team and mechanism launched
2020
Global rebranding to ClinChoice
Global ERP upgraded and SOP & QMS system upgraded.
China Development: Acquisition of Chinese Medicine Clinical CRO Qihuang
2021
Services Focused on Emerging Biopharmaceuticals and Innovative Drugs
China Development: Acquisition of Phase I clinical site Accube
Series E financing: led by Legend Capital, followed by Taikang Asset and others
2022
Global Clinical Operations Network Established
Global Growth: Acquisition of European Clinical CRO CROMSOURCE
Deepened collaboration with hospital centers (Star Site)
2023+
Expansion of international cooperation and cross-border clinical outsourcing project implementation
Global Development: Acquisition of CSI and continued expansion in Southeast Asia and Australia and New Zealand markets.
K&L was founded in Philadelphia, USA.
•FMD was founded in Tianjin.
• Series A financing led by Draper Fisher Jurvetson.
iMed was founded in the United States and India.
•International Development: Merger with K&L;
•Series B financing: led by Lilly Asia Ventures.
•ClinChoice K.K .was founded.
•Global Development: Merger with iMed
•Series C financing: led by Lilly Asia Ventures and Draper Fisher Jurvetson
•Series D Financing: Led by Goldman Sachs and Lilly Asia Ventures
•New management team and mechanism launched
•Global rebranding to ClinChoiceGlobal ERP upgraded and SOP & QMS system upgraded.China Development: Acquisition of Chinese Medicine Clinical CRO Qihuang
•Services Focused on Emerging Biopharmaceuticals and Innovative Drugs
•China Development: Acquisition of Phase I clinical site Accube
•Series E financing: led by Legend Capital, followed by Taikang Asset and others
•Global Clinical Operations Network Established
•Global Growth: Acquisition of European Clinical CRO CROMSOURCE
•Deepened collaboration with hospital centers (Star Site)
•Expansion of international cooperation and cross-border clinical outsourcing project implementation
•Global Development: Acquisition of CSI and continued expansion in Southeast Asia and Australia and New Zealand markets.